Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular OutcomesRohan Khera, Patrick B. Ryan, Shounak Chattopadhyay et al.|Journal of the American College of Cardiology|2024Cited by 33
Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DMRohan Khera, Marc A. Suchard, Lovedeep Singh Dhingra et al.|BMJ Medicine|2023Cited by 27
Vaccine Safety Surveillance Using Routinely Collected Healthcare Data—An Empirical Evaluation of Epidemiological DesignsMartijn J. Schuemie, Marc A. Suchard, Faaizah Arshad et al.|Frontiers in Pharmacology|2022Cited by 19
Bias, Precision and Timeliness of Historical (Background) Rate Comparison Methods for Vaccine Safety Monitoring: An Empirical Multi-Database AnalysisXintong Li, Daniel Prieto‐Alhambra, Lana Yin Hui Lai et al.|Frontiers in Pharmacology|2021Cited by 13
Reproducible variability: assessing investigator discordance across 9 research teams attempting to reproduce the same observational studyAnna Ostropolets, Patrick Ryan, Yasser Albogami et al.|Journal of the American Medical Informatics Association|2023Cited by 12